In the high-stakes world of biopharmaceutical manufacturing, the adage "knowledge is power" is more than a cliché—it is a financial and operational imperative. As the industry shifts toward complex advanced therapies and leans heavily on contract development and manufacturing organizations (CDMOs), a silent crisis is unfolding. Valuable "tacit knowledge"—the nuanced, experience-based expertise that cannot be captured in a standard operating procedure (SOP)—is being lost at an alarming rate.
This loss, occurring primarily during the precarious process of technology transfer, threatens to derail manufacturing timelines, inflate costs, and, in worst-case scenarios, jeopardize patient safety. As the workforce ages and industry-wide layoffs reshape the manufacturing landscape, the biopharma sector is facing a reckoning: how to preserve the institutional intelligence that keeps life-saving drugs on the market.
The Mechanics of a Knowledge Gap
Technology transfer is the backbone of biopharma development. It represents the movement of processes from R&D to pilot plants, and eventually to large-scale commercial manufacturing sites. While the industry has mastered the transfer of codified data—analytical specifications, equipment settings, and batch records—it has consistently failed to bridge the gap for tacit knowledge.
Ryan Chen, director of Product Marketing at ValGenesis, underscores the relentless nature of this challenge. "Technology transfer occurs repeatedly across the lifecycle: from CMC development to first GMP clinical supply, and further down to commercial scale, between manufacturing sites and even post-approval when capacity, network or process/method changes are required," Chen explains.
When this cycle is interrupted by staff turnover or site relocation, the "why" behind the "what" is often lost. The documentation might tell a manufacturer how to run a bioreactor, but it rarely captures the intuitive adjustments an experienced operator makes when they notice a subtle shift in cell behavior—a gap that is proving catastrophic as the industry scales.
A Chronology of Erosion: From Lab Bench to Market
To understand the scope of the problem, one must view the lifecycle of a biopharmaceutical product as a series of fragile hand-offs, each susceptible to data loss.
Phase 1: The Academic-to-Industry Hand-off
The lifecycle begins in academia, where innovation is high and structure is low. Research processes are designed for speed and discovery, not for the rigid, reproducible demands of Good Manufacturing Practice (GMP). When a promising therapy moves to industry, the documentation often fails to account for the "failed attempts" that taught the original researchers what not to do. This "negative knowledge" is rarely published, meaning the new industry team is forced to repeat costly errors to rediscover the boundaries of the process.
Phase 2: The CDMO Integration
As of 2022, over 86% of biopharma companies outsource at least some manufacturing activities. While this model provides essential agility, it creates a "knowledge silo." When a drug sponsor hands a process over to a CDMO, the implicit understanding of the drug’s variability stays with the original team. If the CDMO is not integrated into the early-stage development process, they inherit a black box.
Phase 3: The Demographic and Economic Squeeze
The erosion is accelerated by external forces. The "Silver Tsunami"—the 11,000 baby boomers reaching retirement age daily in the U.S.—is stripping the industry of its most experienced process engineers and subject matter experts. Simultaneously, the industry is grappling with economic volatility; 2025 saw a 16% rise in biopharma layoffs, with manufacturing and CDMO roles disproportionately affected. When these individuals exit, they take decades of "tribal knowledge" with them, leaving behind documented procedures that are, in practice, incomplete.
Supporting Data: The High Cost of Silence
The financial implications of poor knowledge management are staggering. Merck has reported an estimated $125 million in value attributable to rigorous knowledge management strategies over a ten-year period. Conversely, the cost of "knowledge leakage" manifests as delayed regulatory approvals, failed validation batches, and extended timelines for commercial scale-up.
Industry bodies have begun to sound the alarm. The PDA (Parenteral Drug Association) Technical Report No. 65 explicitly identifies the capture of tacit knowledge as a best practice, emphasizing that poor transfer processes directly affect the patient experience. Despite this, the industry remains trapped in a document-centric mindset. The ISPE Good Practice Guide on Knowledge Management points out that because the industry is so heavily regulated, it tends to prioritize "what is written down" over "what is understood," leaving tacit knowledge arguably underappreciated.
The High Stakes of Advanced Modalities
The challenge of knowledge retention is magnified tenfold by the rise of advanced therapies, particularly cell and gene therapies (CGT). Unlike traditional small-molecule drugs, which rely on chemical synthesis and terminal sterilization, CGT products are biological entities.
"Advanced modalities introduce greater biological variability, complex potency assays, aseptic processing requirements and sensitivity to operator technique," says Chen.
In the production of CAR-T cell therapies, for example, the "operator technique" is not a minor variable; it is a critical quality attribute. The manual handling of cell isolation, expansion, and harvesting means that the specific tactile "feel" and timing of an operator can dictate the ultimate yield and potency of the product. When an operator interprets flow cytometry data, their subjective expertise—honed over years of observation—often fills the gaps left by standard operating procedures. If that operator leaves, the process efficacy can shift, potentially leading to inconsistencies that are difficult to diagnose in a controlled, sterile environment.
Official Responses and Regulatory Outlook
Despite the clear risks, there is currently no global regulatory framework that mandates specific methods for capturing tacit knowledge. Regulators like the FDA and EMA emphasize the need for "Process Analytical Technology" (PAT) and "Quality by Design" (QbD), but these frameworks focus on measurable data points.
Industry leaders argue that the solution lies in a cultural shift rather than a regulatory mandate. The recommendation from experts like Chen is a "design for transfer" philosophy. This involves:
- Institutionalizing Knowledge Management: Moving away from paper-based silos toward digital systems that can track not just the process, but the "intent" and "logic" behind process decisions.
- Early Analytical Readiness: Investing in robust characterization of the product in the lab phase so that the transition to the factory floor is less dependent on human intuition.
- Strategic Partner Selection: Choosing CDMOs based on their "modality expertise" rather than just their available capacity.
- Governance and Change Control: Treating tech transfer as a core competency that begins during Phase 1 trials, rather than as a late-stage operational hurdle to be cleared before commercial launch.
Implications for the Future of Biopharma
The biopharma industry stands at a crossroads. As we move further into an era of personalized medicine and highly complex, patient-specific therapies, the margin for error is shrinking. If the industry continues to treat knowledge management as a "nice-to-have" rather than a foundational pillar of manufacturing, it risks stalling the very innovations that define the modern medical landscape.
The loss of tacit knowledge is not just an operational nuisance; it is a degradation of the scientific heritage that allows complex therapies to reach the patients who need them. Organizations that successfully bridge the gap between documented procedures and human expertise will likely emerge as the market leaders of the next decade. Those that fail to institutionalize this wisdom will find themselves trapped in an endless, expensive cycle of "reinventing the wheel" every time a process moves from one site to another.
In the end, technology transfer must evolve from a bureaucratic milestone into a robust knowledge-transfer ecosystem. The future of biopharmaceutical manufacturing depends not just on what we know, but on how effectively we can pass that knowledge to the next generation of scientists and operators who will hold the industry’s future in their hands.
About the Author
